Establishing cost-effectiveness of genetic targeting of cancer therapies

Valesca P. Retèl, E.J.Th. Rutgers, M.A. Joore, W.H. van Harten

Research output: Contribution to journalArticleAcademicpeer-review

45 Downloads (Pure)


The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to help decision-making in an uncertain time of development
Original languageEnglish
Pages (from-to)52-54
Number of pages3
JournalEJHP practice
Issue number6
Publication statusPublished - 2008


Dive into the research topics of 'Establishing cost-effectiveness of genetic targeting of cancer therapies'. Together they form a unique fingerprint.

Cite this